<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181476</url>
  </required_header>
  <id_info>
    <org_study_id>13223</org_study_id>
    <nct_id>NCT04181476</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects</brief_title>
  <official_title>Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>L'Oreal</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of topical products in providing
      protection against the visible light and ultraviolet A1 (UVA1) part of sunlight. Ultraviolet
      radiation and visible light are both components of sunlight that reach the earth. It is
      important to test these topical products against visible light and UVA1 because our current
      sunscreens may not protect against these very well.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Investigator's Global Assessment (IGA)</measure>
    <time_frame>through study completion, an average of 1 week</time_frame>
    <description>Assesses erythema and pigmentation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Colorimetry</measure>
    <time_frame>through study completion, an average of 1 week</time_frame>
    <description>Measures erythema and pigmentation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Diffuse Reflectance Spectroscopy</measure>
    <time_frame>through study completion, an average of 1 week</time_frame>
    <description>Measures erythema and pigmentation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Sun Damaged Skin</condition>
  <arm_group>
    <arm_group_label>Topical products and Untreated areas</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The subject will serve as their own control. Four different products will be tested.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunscreening Agents</intervention_name>
    <description>Four different sunscreens</description>
    <arm_group_label>Topical products and Untreated areas</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age 18 and older

          -  Patients Fitzpatrick skin phototype (SPT) III-IV with normal skin health

          -  Patient able to understand requirements of the study and risks involved

        Exclusion Criteria:

          -  A recent history of vitiligo, melasma, and other disorders of pigmentation with the
             exception of post inflammatory hyperpigmentation

          -  A history of a relevant skin condition on any part of the patient's body (e.g. atopic
             dermatitis, eczema, vitiligo, sun burn, etc.

          -  A known history of photodermatoses

          -  A known history of photosensitivity disorders

          -  A known history of melanoma or non-melanoma skin cancers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iltefat Hamzavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford HS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Parks-Miller</last_name>
    <phone>313-916-0426</phone>
    <email>amiller5@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shanthi Narla, MD</last_name>
    <phone>313-916-0412</phone>
    <email>snarla1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard,</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Parks-Miller</last_name>
      <phone>313-916-0426</phone>
      <email>amiller5@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Iltefat H. Hamzavi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Iltefat Hamzavi</investigator_full_name>
    <investigator_title>Senior Staff Physician, Director of Investigator-Initiated Trials</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

